Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SpareBank 1 Markets in connection with its partnership with Swedbank
Mandate

Vinge advises SpareBank 1 Markets in connection with its partnership with Swedbank

March 04, 2025 M&A Financial Regulatory

The partnership between SpareBank 1 Markets and Swedbank aims to create a leading Nordic investment bank. As part of the transaction, SpareBank 1 Markets will receive Swedbank’s Corporate Finance and DCM High-Yield business in Sweden and establish a branch in Stockholm through which the business operations will be conducted.

Pursuant to the partnership, Swedbank will become part-owner of SpareBank 1 Markets with a 20% stake thereby strengthening the position of both banks in the Nordic market and creating new opportunities for expansion in investment banking.

The transaction is subject to regulatory approvals and customary closing conditions.

Vinge’s team primarily consists of Samra Tesser, Nils Unckel, Anton Sjökvist and Gustav Wahlberg.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025